Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market
Glucagon-like peptide-1 receptor (GLP-1R) therapeutics are not the only contributors to the rapidly growing global obesity market. The non-GLP-1R landscape, including calcitonin receptor (CR) products, is emerging, with sales expected to surge 50-fold over the next five years. This shift highlights how pharmaceutical companies are diversifying beyond dominant GLP-1R agonists to capture new segments in the fight against obesity.
The Growing Obesity Crisis and Pharmaceutical Response
Obesity is a chronic condition, characterised by excessive fat, which increases the risk of serious diseases such as type 2 diabetes. In the US, the obesity rate has steadily increased, with the condition affecting over 100 million adults, 40%-42% of the adult population. This epidemic has fueled unprecedented demand for effective treatments, propelling the pharmaceutical market for obesity drugs into rapid expansion.
GlobalData's sales and forecast tool predicts that obesity drugs will collectively generate $172.6bn in 2031, a rise of 139% from the $72.2bn forecast for 2026. Much of this growth has been driven by the commercial successes of GLP-1R agonists, such as Novo Nordisk's semaglutide (Wegovy) and Eli Lilly's tirzepatide (Zepbound). These drugs mimic the GLP-1 hormone, which regulates appetite, slows gastric emptying, and promotes insulin secretion, leading to significant weight loss in clinical trials.
Understanding GLP-1R Agonists: The Current Market Leaders
GLP-1R agonists work by activating receptors in the gut and brain to reduce hunger signals and improve metabolic control. Their efficacy has transformed obesity management from lifestyle interventions alone to pharmacotherapy as a cornerstone. However, limitations such as gastrointestinal side effects, muscle loss concerns, and high costs have spurred interest in complementary mechanisms.
The Rise of Non-GLP-1R Obesity Drugs
Despite their current dominance, GLP-1R agonists are not the only contributors to future growth. Currently, there is limited interest in the non-GLP-1R obesity field, as sales for obesity drugs targeting alternative mechanisms are only forecast to generate a mere $310m in 2026. However, by 2031, this figure is expected to surge almost 50-fold, indicating a strong market potential outside of GLP-1R drugs.
Due to a limited number of commercialised products, growth for the non-GLP-1R obesity landscape is forecast to remain low for the first two years (2026-2028), with $1.7bn estimated to be generated in 2028. From here, the market is expected to grow rapidly at a compound annual growth rate of 110.8%, ultimately reaching $15.5bn globally in 2031. The first launches for the obesity drugs targeting CR and inhibin beta E chain are estimated for 2028, facilitating the growth expected from this year.
Calcitonin Receptor (CR) Drugs: The Leading Non-GLP-1R Contender
By 2031, CR drugs are forecast to be the top non-GLP-1R obesity drug type, generating $5.43bn, equivalent to 35% of all sales attributed to non-GLP-1R drugs. Calcitonin receptors, involved in regulating energy balance and fat metabolism, offer a novel pathway distinct from GLP-1R. These drugs may provide additive benefits when combined with GLP-1 agonists or serve as alternatives for patients intolerant to current therapies.
The obesity heavyweights, Eli Lilly and Novo Nordisk, are expected to extend their dominance beyond GLP-1Rs, as they account for the top two CR drugs. By 2031, Eli Lilly's eloralintide is forecast to lead the pack, generating $3.4bn, followed by the $771m attributed to Novo Nordisk's cagrilintide. This expansion by the two largest obesity players into CR drugs suggests both companies are actively diversifying beyond GLP-1R drugs to secure early positions in emerging segments of obesity.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Other Promising Non-GLP-1R Targets
Elsewhere, the melanocortin receptor 4 represents the third largest non-GLP-1R obesity market. In 2031, this landscape is forecast to generate $2bn, a growth of over seven times the value for 2026. Sales for this category are solely attributed to one drug, Rhythm Pharmaceuticals' setmelanotide (Imcivree), highlighting the limited competition within this space. Setmelanotide targets genetic forms of obesity by activating melanocortin-4 receptors in the brain, which control hunger and energy expenditure.
Inhibin beta E chain targets are also on the horizon, with launches anticipated around 2028, contributing to the overall non-GLP-1R momentum.
Strategic Diversification by Pharma Giants
Companies are strategically investing in novel mechanisms to reduce reliance on this single drug class, securing positions within emerging segments. Eli Lilly and Novo Nordisk's moves into CR exemplify this trend, potentially leading to combination therapies that enhance weight loss efficacy while mitigating side effects like nausea or cardiovascular strain from GLP-1R drugs alone.
Patient Considerations for Emerging Therapies
For patients exploring obesity treatments, non-GLP-1R options could expand choices, especially for those with comorbidities or suboptimal responses to semaglutide or tirzepatide. Discuss with your healthcare provider factors like genetic predispositions (e.g., for setmelanotide), potential side effects such as injection-site reactions for CR drugs, and monitoring needs. Tools like Shotlee can help track symptoms, side effects, or medication schedules during transitions to new therapies.
Market Implications and Future Outlook
The obesity market is beginning to diversify, with non-GLP-1R drugs demonstrating strong long-term market potential as new mechanisms move closer to commercialisation. The key launches anticipated for 2028 are expected to facilitate the shift of this market from slow early growth to rapid expansion, reflecting confidence in alternative targets such as the CR. GLP-1R therapies are expected to remain the dominant force within obesity. However, this diversification is likely to drive competition, expand treatment options, and reshape the long-term structure of the obesity pharmaceutical landscape.
Key Takeaways
- Non-GLP-1R obesity drugs forecast to grow from $310m in 2026 to $15.5bn in 2031 (50-fold surge).
- CR drugs lead with $5.43bn by 2031; Eli Lilly's eloralintide ($3.4bn) and Novo Nordisk's cagrilintide ($771m) top the list.
- Melanocortin-4 drugs like setmelanotide to reach $2bn.
- Total obesity market hits $172.6bn in 2031, up 139% from 2026.
- Diversification reduces reliance on GLP-1R agonists like semaglutide (Wegovy) and tirzepatide (Zepbound).
What This Means for Patients and Providers
These forecasts signal more personalized obesity management. Patients may soon access multi-mechanism therapies for sustained weight loss. Providers should stay informed on 2028 launches to optimize regimens, balancing efficacy, tolerability, and cost.
In summary, while GLP-1R drugs drive current growth, emerging targets like CR are set to claim a significant share, fostering innovation in metabolic health.